Efficacy of subconjunctival bevacizumab injection in corneal neovascularisation.
Article
in English
| IMSEAR
| ID: sea-134488
ABSTRACT
Aim:
To evaluate the therapeutic effect of subconjunctival Bevacizumabon corneal neovascularisationDesign:
A prospective randomized noncomparative study.Method:
The charts of 10 consecutive patients with corneal neovascularisation who received single S.C. inj. of Bevacizumab (2.5mg/0.1ml) were reviewed. Digital photographs of the cornea were taken pre & post injection & then at 1 wk,3wk & 2months duration. Digital photographs of the cornea were analyzed to determine the length, density, extent, centricity of corneal neovascularisation and the area of cornea covered by neovascularisation as a percentage of the total corneal area.Results:
Subconjunctival injection of Bevacizumab (Avastin) caused significant regression of corneal neovascularisation in 1 pt, partial regression in 6 pts and no effect in 3 pts as measured by length and surface area of neovascularisation. No significant ocular or systemic complications were found.Conclusion:
Subconjunctival inj. of Bevacizumab is effective in regressing corneal neovascularisation.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Sodium Glutamate
/
Humans
/
Conjunctivitis, Acute Hemorrhagic
/
Corneal Neovascularization
/
Injections, Intraocular
/
Antibodies, Monoclonal, Humanized
Type of study:
Controlled clinical trial
Language:
English
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS